Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Failed Tyrosine Kinase Inhibitors”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07158840
What this trial is testing

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Who this might be right for
Non-Small Cell Lung Cancer
Akeso 60
Testing effectiveness (Phase 2)UnknownNCT03257124
What this trial is testing

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Who this might be right for
Non-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors
Samsung Medical Center 80
Testing effectiveness (Phase 2)Study completedNCT02810990
What this trial is testing

Bosutinib in Elderly Chronic Myeloid Leukemia

Who this might be right for
Chronic Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 65
Not applicableStudy completedNCT00922025
What this trial is testing

Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 186
Testing effectiveness (Phase 2)UnknownNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 114
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableNo Longer AvailableNCT00655252
What this trial is testing

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Who this might be right for
Metastatic Renal Cell Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT01456676
What this trial is testing

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Who this might be right for
Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 11
Testing effectiveness (Phase 2)UnknownNCT04872634
What this trial is testing

Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

Who this might be right for
Non-small Cell Lung Cancer
NKMAX Co., Ltd. 24
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Testing effectiveness (Phase 2)Study completedNCT01914484
What this trial is testing

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Who this might be right for
Chronic Phase Chronic Myeloid LeukemiaAccelerated Phase Chronic Myeloid LeukemiaBlastic Phase Chronic Myeloid Leukemia+2 more
University Health Network, Toronto 4
Large-scale testing (Phase 3)Study completedNCT00471328
What this trial is testing

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

Who this might be right for
Gastrointestinal Stromal Tumors
Novartis Pharmaceuticals 248
Testing effectiveness (Phase 2)Study completedNCT00462943
What this trial is testing

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Who this might be right for
Chronic Myeloid Leukemia
Teva Branded Pharmaceutical Products R&D, Inc. 100
Large-scale testing (Phase 3)Study completedNCT03802240
What this trial is testing

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd. 492
Large-scale testing (Phase 3)Ended earlyNCT02322281
What this trial is testing

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 149
Large-scale testing (Phase 3)UnknownNCT05311943
What this trial is testing

Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Who this might be right for
OlverembatinibChronic Myeloid Leukemia, Chronic PhaseTyrosine Kinase Inhibitors
Shenzhen Second People's Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT02078960
What this trial is testing

Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

Who this might be right for
Chronic Myeloid Leukemia
Teva Branded Pharmaceutical Products R&D, Inc. 10
Testing effectiveness (Phase 2)WithdrawnNCT02923986
What this trial is testing

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Who this might be right for
Chronic Myelogenous Leukemia, Ph1-PositiveAcute Myeloid LeukemiaMyelodysplastic Syndrome
Bio-Path Holdings, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT05184712
What this trial is testing

Phase 3 Clinical Study of AK112 for NSCLC Patients

Who this might be right for
Non-Squamous Non-small Cell Lung Cancer
Akeso 322
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Load More Results